SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (53)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Zhou, S.
Right arrow Articles by Lee, E. J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, S.
Right arrow Articles by Lee, E. J. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Pharmacokinetic Interactions of Drugs with St John’s Wort

Shufeng Zhou

Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore.,phazsf{at}nus.edu.sg

Eli Chan

Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore.

Shen-Quan Pan

Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore.

Min Huang

Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510089, PR China.

Edmund Jon Deoon Lee

Department of Pharmacology, Faculty of Medicine, National University of Singapore, Singapore.

There is a worldwide increasing use of herbs which are often administered in combination with therapeutic drugs, raising the potential for herb-drug interactions. St John’s wort (Hypericum perforatum) is one of the most commonly used herbal antidepressants. A literature search was performed using Medline (via Pubmed), Biological Abstracts, Cochrane Library, AMED, PsycINFO and Embase (all from their inception to September 2003) to identify known drug interaction with St John’s wort. The available data indicate that St John’s wort is a potent inducer of CYP 3A4 and P-glycoprotein (PgP), although it may inhibit or induce other CYPs, depending on the dose, route and duration of administration. Data from human studies and case reports indicate that St John’s wort decreased the blood concentrations of amitriptyline, cyclosporine, digoxin, fexofenadine, indinavir, methadone, midazolam, nevirapine, phenprocoumon, simvastatin, tacrolimus, theophylline and warfarin, whereas it did not alter the pharmacokinetics of carbamazepine, dextromethorphan, mycophenolic acid and pravastatin. St John’s wort decreased the plasma concentration of the active metabolite SN-38 in cancer patients receiving irinotecan treatment. St John’s wort did not alter the pharmacokinetics of tolbutamide, but increased the incidence of hypoglycaemia. Several cases have been reported that St John’s wort decreased cyclosporine blood concentration leading to organ rejection. St John’s wort caused breakthrough bleeding and unplanned pregnancies when used concomitantly with oral contraceptives. It also caused serotonin syndrome when coadministered with selective serotonin-reuptake inhibitors (e.g. sertaline and paroxetine). Both pharmacokinetic and pharmacodynamic components may play a role in these interactions. Because the potential interaction of St John’s wort with other drugs is a major safety concern, additional systematic research on herb-drug interactions and appropriate regulation in herbal safety and efficacy is needed.

Key Words: cytochrome P450 • drug interactions P-glycoprotein • St John’s wort

Journal of Psychopharmacology, Vol. 18, No. 2, 262-276 (2004)
DOI: 10.1177/0269881104042632


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
X. Tian, B. Swift, M. J. Zamek-Gliszczynski, M. G. Belinsky, G. D. Kruh, and K. L. R. Brouwer
Impact of Basolateral Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 on the Hepatobiliary Disposition of Fexofenadine in Perfused Mouse Livers
Drug Metab. Dispos., May 1, 2008; 36(5): 911 - 915.
[Abstract] [Full Text] [PDF]


Home page
CephalalgiaHome page
N Bonetto, L Santelli, L Battistin, and A Cagnin
Serotonin Syndrome and Rhabdomyolysis Induced by Concomitant Use of Triptans, Fluoxetine and Hypericum
Cephalalgia, December 1, 2007; 27(12): 1421 - 1423.
[Full Text] [PDF]


Home page
The OncologistHome page
S. Marchetti, R. Mazzanti, J. H. Beijnen, and J. H. M. Schellens
Concise Review: Clinical Relevance of Drug Drug and Herb Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein)
Oncologist, August 1, 2007; 12(8): 927 - 941.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
I. Meijerman, J. H. Beijnen, and J. H.M. Schellens
Herb-Drug Interactions in Oncology: Focus on Mechanisms of Induction
Oncologist, July 1, 2006; 11(7): 742 - 752.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
N. B. Sandson, S. C. Armstrong, and K. L. Cozza
An Overview of Psychotropic Drug-Drug Interactions
Psychosomatics, October 1, 2005; 46(5): 464 - 494.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
S. A. Krikorian and D. C. Rudorf
Drug-Drug Interactions and HIV Therapy: What Should Pharmacists Know?
Journal of Pharmacy Practice, August 1, 2005; 18(4): 278 - 294.
[Abstract] [PDF]



Advertisement